Evolving alliance structures

In contrast to this kind of target screening structure, however, several recent CC alliances have been structured in ways that are apparently unique to the CC field and perhaps, in some cases, to even a single biotech participant within this field. 

Pharma/biotech Date Screen CC Lib. Deliver CC Lib. Sell CC Tech. Royalty exclusions  

0 Definition of Excluded Product in the P G/Houghten agreement is confidential. 

With regard to the second subgroup, exclusivity is principally time-limited. Both of the Pharmacopeia alliances in this subgroup are target-related nonetheless, as was mentioned earlier, pharma s license to developed products is not limited to specific 

In the Houghten and ArQule deals, by contrast, a winner takes all situation arises. Partners have essentially equivalent access to CC libraries on a nonexclusive basis, with the option to reserve designated compounds (and derivative libraries) as exclusive on the basis of observed biological activity and the payment of a corresponding milestone. All undesignated compounds revert to the biotech for continued licensure or internal use. 

---